---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-006818"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T15:34:02.900108+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Corvus reports Q3 net loss $6.0M, cash $32.2M; soquelitinib Phase 3 trial protocol finalized

## Summary
- Net loss $6.0M vs $14.8M in Q3 2022; R&D expenses down to $4.0M from $10.4M.
- Cash, equivalents and marketable securities $32.2M as of Sept 30, 2023 (Dec 31, 2022: $42.3M).
- ATM program raised $7.8M net from 2.46M shares; FY 2023 cash burn guidance $22-23M.
- Soquelitinib Phase 3 registrational trial for relapsed PTCL protocol finalized; enrollment expected Q2 2024; Phase 2 in RCC planned early 2024.
- New soquelitinib data accepted for ASH Dec 2023; preclinical autoimmune/allergy data published.

## SEC filing metadata
- accession: 0001171843-23-006818
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184323006818/0001171843-23-006818-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184323006818/f8k_110723.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-006818
- JSON: https://secwatch.observer/filing/0001171843-23-006818.json
- Plain text: https://secwatch.observer/filing/0001171843-23-006818.txt

## Key facts
- Earnings Releases
  Corvus Pharmaceuticals, Inc. reported the third quarter ended September 30, 2023 results: net income The net loss for the three months ended September 30, 2023 was $6.0 million.
  - Period: the third quarter ended September 30, 2023
  - Net income: The net loss for the three months ended September 30, 2023 was $6.0 million
  - Result: reported results
  source text: Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626971/000117184323006818/0001171843-23-006818-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.